Salarius Pharmaceuticals, Inc. and VolitionRx Limited announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition's Nu.Q(R) technology to support further development of Salarius' clinical stage drug, seclidemstat. Seclidemstat, a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression. Nu.Q(R) has been developed as simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of life-altering diseases including cancer in humans and animals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.411 USD | -4.42% | -11.27% | -36.77% |
05-13 | Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-25 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.77% | 1.96M | |
+51.85% | 57.87B | |
+41.14% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- SLRX Stock
- News Salarius Pharmaceuticals, Inc.
- Salarius Pharmaceuticals and VolitionRx Enters into Research and Development Collaboration Agreement